Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Pharmacogenet Genomics. 2011 Jan;21(1):1–9. doi: 10.1097/fpc.0b013e328340bc5a
Financial Relationships
A. John Rush, M.D.
(Last 5 Years)
Commercial Interest What I Received My Role
Advanced Neuromodulation Systems Consulting Fee Consultant
AstraZeneca Consulting Fee Consultant
Best Practice Project Management Consulting Fee Consultant
Bristol-Myers Squibb/Otsuka Consulting Fee Consultant
Cyberonics Consulting Fee/Honoraria Consultant/Speaker
Forest Pharmaceuticals Consulting Fee/Honoraria Consultant/Speaker
Gerson Lehrman Group Consulting Fee Consultant
GlaxoSmithKline Consulting Fee/Honoraria Consultant/Speaker
Guilford Publications Royalties Author
Healthcare Technology Systems Royalties Author
Jazz Pharmaceuticals Consulting Fee Consultant
Magellan Health Services Consulting Fee Consultant
Merck & Company Consulting Fee Consultant
Neuronetics Consulting Fee Consultant
National Institute of Mental Health Research Support Researcher
Novartis Pharmaceuticals Consulting Fee Consultant
Ono Pharmaceuticals Consulting Fee Consultant
Organon Consulting Fee Consultant
Otsuka Pharmaceuticals Consulting Fee Consultant/Speaker
Pamlab Consulting Fee Consultant
Pfizer Consulting Fee/Income Consultant/Stock Holder
Society of Biological Psychiatry Stipend Treasurer
Stanley Medical Research Institute Research Support Researcher
Transcept Pharmaceuticals Consulting Fee Consultant
Urban Institute Consulting Fee Consultant
Wyeth Ayerst Consulting Fee Consultant